17 results
The objective of the present trial is to investigate the safety of an allogenic tumor cell lysate loaded onto autologuous dendritic cells (AlloDen) in patients with malignant mesothelioma (MM). Heretoo we will perform a phase I study with a…
The main purpose of this study is to assess whether the study drug anetumab ravtansine is more effective than treatment with vinorelbine in patients with stage IV, mesothelin overexpressing malignant pleural mesothelioma. Efficacy will be measured…
Primary Objective:* To determine if TTFields in combination with pemetrexed/platinum improves overall survival (OS) compared to historical control in patients with unresectable mesothelioma.Secondary Objectives:* To evaluate the overall response…
The primary objective is to determine the effect on progression-free survival (PFS) of adding MORAb-009 to the combination of pemetrexed and cisplatin in the treatment of subjects with unresectable malignant pleural mesothelioma (MPM). (Protocol ch…
To test the impact of the addition of axitinib to standard chemotherapy treatment on histology samples
Primary objective is to investigate whether palliative pleurectomy / decortication after 4-6 courses of standard chemotherapy with cisplatin and pemetrexed will lead to a doubling of the overall survival compared to a control group which will…
To find activity in this new class of drugs
Primary Objective* To determine the DCR (disease control rate) at 12 weeks of nivolumab monotherapy in patients with progressive MPM.Secondary Objectives* To determine the safety of nivolumab monotherapy in patients with progressive MPM* To…
PEMbrolizumab Plus Lenvatinib In Second Line And Third Line Malignant Pleural MEsotheLiomA Patients.
Primary: 1. To determine the objective response rate (ORR), defined by Modified (i)RECIST criteria for pleural mesothelioma, of the combination of pembrolizumab - lenvatinib in pre-treated patients with MPM. Secondary:1. To describe the safety of…
The primary objective of this study is to evaluate the overall survival (OS) rate (determined from the time of randomization in the study) of subjects who receive dendritic cell immunotherapy with MesoPher plus best supportive care (BSC) compared to…
This study has been transitioned to CTIS with ID 2024-516738-36-00 check the CTIS register for the current data. The primary purpose of this study is to determine the maximum tolerable dose (MTD) of IP monotherapy with paclitaxel for patients with…
This study has been transitioned to CTIS with ID 2024-514054-70-00 check the CTIS register for the current data. To assess whether (neo)-adjuvant DCT in combination with eP/D is feasible in early stage epithelioid MPM patients after first-line…
This study has been transitioned to CTIS with ID 2023-508369-34-00 check the CTIS register for the current data. The purpose of this first-in-human (FIH) study is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD…
To investigate the feasibility of immediate P/D followed by cisplatin/pemetrexed chemotherapy (or carboplatin/pemetrexed chemotherapy) or deferred P/D after cisplatin/pemetrexed chemotherapy (or carboplatin/pemetrexed chemotherapy) in patients with…
To assess the feasibility of administering DCBI after CRS-HIPEC in patients with malignant peritoneal mesothelioma.
Primary objectives:1. Determine the potential improvement of the duration of progression-free survival by maintenance treatment with gemcitabine. Secondary objectives:1. To compare the objective radiological response (ORR) rate2. To compare overall…
The primary objective of the study is the disease control rate (DCR) at 12 weeks of the combination treatment of Nivolumab and Ipilimumab in patients with progressive MPM.The secondary objectives are:- to determine the safety profile of the…